MEDI8897 Market Size, Forecast, and Market Insight - 2032

“MEDI8897 Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the MEDI8897 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MEDI8897 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MEDI8897 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary

MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose. Due to its extended half-life technology, nirsevimab is being developed as a single dose for all infants experiencing their first RSV season and infants with specific conditions, such as congenital heart disease or chronic lung disease, entering their first and second RSV season.

Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer rapid and direct protection against disease. With nirsevimab, the goal is to provide rapid and direct protection to the infant through a single immunization. It is the first potential immunization to show protection against RSV in infants in a Phase III trial.

Nirsevimab is being developed and commercialized by AstraZeneca in collaboration with Sanofi and is the first single-dose preventative option for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. The FDA has indicated it will work to expedite its review. The Prescription Drug User Fee Act date, the FDA target action date for its decision, is in the third quarter of 2023. If approved at that time, nirsevimab will be available in the US for the 2023/2024 RSV season.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MEDI8897 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on MEDI8897 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MEDI8897 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MEDI8897.
• The report contains forecasted sales of MEDI8897 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for MEDI8897 in RSV.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MEDI8897 Analytical Perspective

In-depth MEDI8897 Market Assessment

This report provides a detailed market assessment of MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

MEDI8897 Clinical Assessment

The report provides the clinical trials information of MEDI8897 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MEDI8897 dominance.
• Other emerging products for RSV are expected to give tough market competition to MEDI8897 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.
• Our in-depth analysis of the forecasted sales data of MEDI8897 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MEDI8897 in RSV.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of MEDI8897?
• What is the clinical trial status of the study related to MEDI8897 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MEDI8897 development?
• What are the key designations that have been granted to MEDI8897 for RSV?
• What is the forecasted market scenario of MEDI8897 for RSV?
• What are the forecasted sales of MEDI8897 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MEDI8897 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

This product will be delivered within 2 business days.